← All trials
NCT06733675
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 7, 2025
- Primary completion
- Mar 7, 2025
- Completion date
- Sep 10, 2025
- First posted
- Dec 13, 2024
- Last posted
- Dec 18, 2024
- Enrollment
- 46
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- VenatoRx Pharmaceuticals, Inc.Lead sponsor
- Department of Health and Human ServicesCollaborator
- VenatoRx Pharmaceuticals, Inc.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.